Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.56 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.56 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 10/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL7212015 | 0.87 | LMNA (0.43) | LMNATSHRMAPK1SCN4ASCN5A | |
| Oxcarbazepine SCHEMBL28141318 | 0.78 | ALDH1A1 (0.63) | LMNATSHRMAPK1USP2ALDH1A1 | |
| Doxepin SCHEMBL7181119 | 0.77 | HRH1 (0.51) | LMNATSHRALDH1A1CYP1A2 | |
| Gabapentin SCHEMBL2862353 | 0.77 | ALDH1A1 (0.92) | LMNATSHRMAPK1USP2ALDH1A1 | |
| Carbamazepine SCHEMBL31685158 | 0.75 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL6477112 | 0.75 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29360181 | 0.75 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL21639 | 0.75 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 0.75 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL1421962 | 0.73 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136120-A1 | TRANSDERMAL DELIVERY KITS | ASCLEMED USA INC DBA ENOVACHEM MFG (US) | 2016-05-19 | — | — | US | claimed |
| US-20150045437-A1 | TRANSDERMAL DELIVERY KITS | ASCLEMED USA, INC. dba EnovaChem Manufacturing | 2015-02-12 | — | — | US | claimed |
| US-20210161915-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | ASARINA PHARMA APS (DK) | 2021-06-03 | — | — | US | disclosed |
| EP-3773599-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | Asarina Pharma ApS (DK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193138-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | ASARINA PHARMA APS (DK) | 2019-10-10 | — | — | WO | disclosed |
| CN-110256418-A | The benzamide that 1,3- thiazol-2-yl replaces | 拜耳公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-107207507-A | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2017-09-26 | — | — | CN | disclosed |
| EP-1093348-A4 | METHODS AND TRANSDERMAL COMPOSITIONS FOR PAIN RELIEF | PHARMACEUTICALS APPLIC ASOCIAT (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6572880-B2 | Transdermal adminitsering mixture of amine compound in carrier | PHARMACEUTICAL APPLICATIONS ASSOCIATES LLC | 2003-06-03 | — | — | US | disclosed |
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6479074-B2 | MIXTURE CONTAINING AMINE | PHARMACEUTICAL APPLICATIONS ASSOCIATES LLC | 2002-11-12 | — | — | US | disclosed |
| WO-2002053187-A2 | METHODS AND TRANSDERMAL COMPOSITIONS FOR PAIN RELIEF | PHARMACEUTICALS APPLICATIONS ASSOCIATES, LLC (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| EP-1093348-A1 | METHODS AND TRANSDERMAL COMPOSITIONS FOR PAIN RELIEF | Pharmaceuticals Applications Asociates, LLC (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000000120-A9 | METHODS AND TRANSDERMAL COMPOSITIONS FOR PAIN RELIEF | PHARMACEUTICALS APPLIC ASOCIAT (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000000120-A1 | METHODS AND TRANSDERMAL COMPOSITIONS FOR PAIN RELIEF | PHARMACEUTICALS APPLICATIONS ASOCIATES, LLC (US) | 2000-01-06 | — | — | WO | disclosed |